CVRx announces availability of additional data supporting long-term benefits of Barostim
15 avr. 2024 07h30 HE
|
CVRx, Inc.
BeAT-HF trial data published in the European Journal of Heart Failure and new abstracts presented at THT conference MINNEAPOLIS, Minn., April 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX)...
CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer
31 janv. 2024 08h00 HE
|
CVRx, Inc.
Appointment effective February 12 following Nadim Yared’s retirement Hykes currently serves as Augmedics’ President and CEO, and has served on CVRx’s Board of Directors since 2022 MINNEAPOLIS, Jan. ...
CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
25 janv. 2024 16h05 HE
|
CVRx, Inc.
MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call on January 25th, 2024
11 janv. 2024 16h30 HE
|
CVRx, Inc.
MINNEAPOLIS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an...
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results and Announces Nadim Yared Retirement Plans
08 janv. 2024 08h30 HE
|
CVRx, Inc.
Fourth quarter revenue expected to be $11.2 million to $11.3 million, representing growth of 56% to 58%Full year revenue expected to be $39.2 million to $39.3 million, representing growth of 74% to...
CVRx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
27 déc. 2023 16h30 HE
|
CVRx, Inc.
MINNEAPOLIS, Dec. 27, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx receives FDA approval for expanded labeling of Barostim
26 déc. 2023 08h05 HE
|
CVRx, Inc.
MINNEAPOLIS, Dec. 26, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the U.S. Food and Drug Administration (FDA) has...
CVRx to Present at the 35th Annual Piper Sandler Healthcare Conference
15 nov. 2023 16h21 HE
|
CVRx, Inc.
MINNEAPOLIS, Nov. 15, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative...
CMS Increases Outpatient Payment for Barostim Procedure
03 nov. 2023 08h00 HE
|
CVRx, Inc.
MINNEAPOLIS, Nov. 03, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that Centers for Medicare and Medicaid Services (CMS)...
CVRx Reports Third Quarter 2023 Financial and Operating Results
26 oct. 2023 16h15 HE
|
CVRx, Inc.
MINNEAPOLIS, Oct. 26, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative...